ChemoCentryx

ChemoCentryx was a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered small molecule therapeutics. Their primary focus was on inflammatory disorders and cancer, with a particular emphasis on targeting chemokine receptors and their ligands. The company's lead product, TAVNEOS (avacopan), was approved for the treatment of adult patients with severe active ANCA-associated vasculitis.